|
Factors
|
No.
|
%
|
|---|
|
Patients enrolled
|
515
|
100.0
|
|
Age (mean ± SD)
|
55.5 ± 11.5
| |
|
Tumor size
| | |
|
Tis
|
6
|
1.2
|
|
T0
|
3
|
0.6
|
|
T1
|
193
|
37.5
|
|
T2
|
272
|
52.8
|
|
T3
|
34
|
6.6
|
|
T4
|
7
|
1.3
|
|
Lymphnode metastasis
| | |
|
negative
|
342
|
66.4
|
|
positive
|
173
|
33.6
|
|
Lymphatic involvement
| | |
|
negative
|
316
|
61.4
|
|
positive
|
199
|
38.6
|
|
Vascular involvement
| | |
|
negative
|
481
|
93.4
|
|
positive
|
34
|
6.6
|
|
Nuclear grade
| | |
|
I/II
|
346
|
67.2
|
|
III
|
169
|
32.8
|
|
Hormone receptor
| | |
|
negative
|
123
|
23.9
|
|
positive
|
392
|
76.1
|
|
HER-2/NEU
| | |
|
negative
|
319
|
61.9
|
|
positive
|
50
|
9.7
|
|
unknown
|
146
|
28.4
|
|
CEA
| | |
|
<5.0
|
452
|
87.8
|
|
>5.1
|
24
|
4.7
|
|
unknown
|
39
|
7.5
|
|
Stage
| | |
|
0
|
6
|
1.2
|
|
I
|
155
|
30.1
|
|
II
|
316
|
61.3
|
|
III
|
38
|
7.4
|
|
Recurrence
| | |
|
negative
|
438
|
85.0
|
|
positive
|
77
|
15.0
|
|
Prognosis
| | |
|
alive
|
488
|
94.8
|
|
dead
|
27
|
5.2
|
